US EditionAlys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata – Optimum Strategic CommunicationsLink to: Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata – Optimum Strategic CommunicationsLink to: Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti
Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata Health Authorities in Canada and the United States provided swift CTA & IND approval allowing for efficient dosing of the first patients Boston, Massachusetts and […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
